Business Description
Autolus Therapeutics PLC
NAICS : 325412
SIC : 2834
ISIN : US05280R1005
Share Class Description:
AUTL: ADRDescription
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 4.52 | |||||
| Equity-to-Asset | 0.3 | |||||
| Debt-to-Equity | 0.48 | |||||
| Debt-to-EBITDA | -0.34 | |||||
| Piotroski F-Score | 1/9 | |||||
| Altman Z-Score | -1.55 | |||||
| Beneish M-Score | -2.93 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 26 | |||||
| 3-Year EBITDA Growth Rate | 33.9 | |||||
| 3-Year EPS without NRI Growth Rate | 24.8 | |||||
| 3-Year FCF Growth Rate | 29.5 | |||||
| 3-Year Book Growth Rate | -45.8 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 6.34 | |||||
| 9-Day RSI | 14.22 | |||||
| 14-Day RSI | 22.28 | |||||
| 6-1 Month Momentum % | 129.37 | |||||
| 12-1 Month Momentum % | 276.22 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.15 | |||||
| Quick Ratio | 6.15 | |||||
| Cash Ratio | 5.35 | |||||
| Days Sales Outstanding | 26.48 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -49.3 | |||||
| Shareholder Yield % | -2.53 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -10337.34 | |||||
| Net Margin % | -12272.26 | |||||
| FCF Margin % | -9221.02 | |||||
| ROE % | -95.86 | |||||
| ROA % | -47.73 | |||||
| ROIC % | -163.31 | |||||
| ROC (Joel Greenblatt) % | -203.79 | |||||
| ROCE % | -41.38 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 444.44 | |||||
| PB Ratio | 6.25 | |||||
| Price-to-Tangible-Book | 6.25 | |||||
| EV-to-EBIT | -5.37 | |||||
| EV-to-EBITDA | -5.59 | |||||
| EV-to-Revenue | 516.55 | |||||
| EV-to-Forward-Revenue | 607.04 | |||||
| EV-to-FCF | -5.6 | |||||
| Price-to-Net-Current-Asset-Value | 57.14 | |||||
| Earnings Yield (Greenblatt) % | -18.62 | |||||
| FCF Yield % | -14.72 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:AUTL
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Autolus Therapeutics PLC Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 1.698 | ||
| EPS (TTM) ($) | -1.2 | ||
| Beta | 1.81 | ||
| Volatility % | 108.93 | ||
| 14-Day RSI | 22.28 | ||
| 14-Day ATR ($) | 0.327787 | ||
| 20-Day SMA ($) | 4.97 | ||
| 12-1 Month Momentum % | 276.22 | ||
| 52-Week Range ($) | 1.69 - 7.45 | ||
| Shares Outstanding (Mil) | 265.93 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Autolus Therapeutics PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Autolus Therapeutics PLC Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Autolus Therapeutics PLC Frequently Asked Questions
What is Autolus Therapeutics PLC(AUTL)'s stock price today?
The current price of AUTL is $4.00. The 52 week high of AUTL is $7.45 and 52 week low is $1.69.
When is next earnings date of Autolus Therapeutics PLC(AUTL)?
The next earnings date of Autolus Therapeutics PLC(AUTL) is 2024-05-03 Est..
Does Autolus Therapeutics PLC(AUTL) pay dividends? If so, how much?
Autolus Therapeutics PLC(AUTL) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers